View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 18, 2011

EMKinetics commences neuromodulation system trial

EMKinetics has begun the TranStim transdermal neuromodulation system trial in patients suffering from urge incontinence and overactive bladder.

EMKinetics has begun the TranStim transdermal neuromodulation system trial in patients suffering from urge incontinence and overactive bladder.

TranStim therapy is based on the fact that posterior tibial nerve stimulation (PTNS) can generate a clinically significant improvement in patients suffering from urge incontinence and an overactive bladder.

EMKinetics co-founder Marshall Stoller said the TranStim system has the potential to safely and consistently provide transdermal PTNS therapy.

The initiation of the pivotal trial follows the closing of EMKinetics’ Series C financing of $8m, led by Allergan.

Following the completion of the study, the company plans to submit data for CE mark approval.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management